HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PRCT
PROCEPT BioRobotics Corporation
PRCT lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PRCT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
PRCT's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PRCT PE Valuation
PRCT has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PRCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
PRCT has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PRCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.03 | -$0.51 |
| Q2 2026 | -$1.95 | -$0.41 |
| Q1 2026 | -$1.83 | -$0.14 |
| Q4 2025 | -$1.72 | +$0.03 |
| Q3 2025 | -$1.52 | +$0.43 |
| Q2 2025 | -$1.54 | +$0.52 |
| Q1 2025 | -$1.69 | +$0.43 |
| Q4 2024 | -$1.75 | +$0.49 |
PRCT has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PRCT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over PRCT on profitability, with a higher operating margin.
PRCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $98.3M | +18% |
| Q2 2026 | $94.5M | +19% |
| Q1 2026 | $83.1M | +20% |
| Q4 2025 | $76.4M | +12% |
| Q3 2025 | $83.3M | +43% |
| Q2 2025 | $79.2M | +48% |
| Q1 2025 | $69.2M | +55% |
| Q4 2024 | $68.2M | +57% |
PRCT's revenue has grown year over year every quarter since early 2021: $98M last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -28% | 0 points |
| Q2 2026 | -29% | -1 points |
| Q1 2026 | -39% | +0.5 points |
| Q4 2025 | -41% | -12 points |
| Q3 2025 | -28% | +11 points |
| Q2 2025 | -28% | +22 points |
| Q1 2025 | -40% | +22 points |
| Q4 2024 | -29% | +39 points |
PRCT's operating margin was −28% last quarter, about level with the same quarter a year ago, near the top of its range since 2020.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PRCT on cash generation, producing positive trailing cash flow while its opponent burns cash.
PRCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.7M | -$149K |
| Q2 2026 | -$22.2M | -$4.4M |
| Q1 2026 | -$41M | -$22.2M |
| Q4 2025 | -$12.2M | +$21.4M |
| Q3 2025 | -$9.5M | +$9.5M |
| Q2 2025 | -$17.8M | -$1.1M |
| Q1 2025 | -$18.8M | +$15.4M |
| Q4 2024 | -$33.6M | -$57K |
PRCT has burned cash in almost every quarter: −$85M over the past year, against −$80M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PRCT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PRCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +259K shares |
| 1 year | +2.9% | +1.6M shares |
| 3 years | +19% | +9M shares |
| 5 years | +39% | +16.1M shares |
PRCT has 57M diluted shares, up 2.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PRCT Net Leverage
PRCT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PRCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.6 | Neutral |
| Stochastic | 60.7 | Neutral |
PRCT's weekly RSI is 55 (neutral) and its Stochastic is 61 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PRCT PE vs Healthcare Sector
PRCT has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PRCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.2 | 22% above |
| 20 week MA | $19.9 | 18% above |
| 50 week MA | $24.5 | 3.8% below |
| 100 week MA | $39.0 | 40% below |
| 200 week MA | $44.3 | 47% below |
PRCT has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PRCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $40.0 | $27.0 | -32% |
| 2022 | $27.0 | $40.9 | +51% |
| 2023 | $40.9 | $41.9 | +2.4% |
| 2024 | $41.9 | $82.0 | +96% |
| 2025 | $82.0 | $32.4 | -60% |
| 2026 YTD | $32.4 | $23.5 | -27% |
PRCT has the edge over HIMS on returns for 2026, with the stronger performance.